BridgePoint Medical, Inc.

BridgePoint Medical, Inc. specializes in medical devices designed to address coronary chronic total occlusions, offering innovative solutions for interventional cardiologists managing cardiovascular diseases. BridgePoint Medical, Inc. was founded in 2002 and operates out of Plymouth, US.

The company focuses on developing medical devices for treating coronary chronic total occlusions. It has undergone strategic pivots to enhance its product offerings and was acquired by Boston Scientific in September 2012. To date, it has completed 5 deals and raised a total of USD 9. 10 mn, with the latest funding round being Series C, which amounted to USD 9.

10 mn, supported by investors including Foundation Medical Partners, New Enterprise Associates, and Polaris Partners. BridgePoint Medical specializes in innovative medical devices aimed at treating coronary chronic total occlusions (CTOs). Its core products include the CROSSBOSS Catheter, which effectively delivers a guidewire through both true lumen and subintimal pathways providing access to CTOs, and the STINGRAY LP System, designed with a focus on reliability and safety to enable precise targeting and re-entry into the true lumen from subintimal positions. These products primarily serve healthcare professionals, including interventional cardiologists, in various medical facilities across North America, Europe, and Asia.

BridgePoint Medical generates revenue through direct sales of its specialized medical devices to healthcare institutions, mainly hospitals and clinics involved in interventional cardiology procedures. Revenue is derived from contracts where hospitals purchase the CROSSBOSS Catheter and STINGRAY LP System tailored to their patient care requirements, and these transactions are integral to sustaining the company’s operations and fostering continued innovation in medical solutions. BridgePoint Medical plans to leverage its recent funding to enhance its research and development efforts, focusing on designing new products for interventional cardiology to improve patient care. The company is aiming to expand its market presence in Europe and Asia over the next few years.

The financial support from the Series C funding will aid in these initiatives, reflecting the company's commitment to advancing its technology and product offerings.